The Role Of The Asymmetric Cell Division Regulator GPSM2 In Mammary Gland Development And Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$647,539.00
Summary
Tissues are built by small populations of progenitor cells which divide unequally to generate different cell types. Recent studies suggest defective progenitor cells are founders of some breast cancers and that progenitor-like cancer cells resist therapy to regenerate tumours. We have shown a progenitor division regulator called GPSM2 controls these cells and inhibits breast cancer. Examination of this new anti-tumour pathway promises to identify therapeutic targets for breast cancer recurrence.
Biological Role And Partners Of The LIM Domain Protein LMO4 In Breast Epithelium
Funder
National Health and Medical Research Council
Funding Amount
$120,181.00
Summary
Breast cancer is the most common cancer affecting women, with 1 in 14 developing this disease. Although treatment of breast cancer has substantially improved over the last few years, 30% of women diagnosed with this cancer will die from it. One major focus of cancer research is the identification of genes involved in tumour development and definition of their precise role in cancer cells. The design of effective therapeutic inhibitors of cancer requires an understanding of the basic molecular an ....Breast cancer is the most common cancer affecting women, with 1 in 14 developing this disease. Although treatment of breast cancer has substantially improved over the last few years, 30% of women diagnosed with this cancer will die from it. One major focus of cancer research is the identification of genes involved in tumour development and definition of their precise role in cancer cells. The design of effective therapeutic inhibitors of cancer requires an understanding of the basic molecular and cellular biology behind the genetic changes thought to contribute to cancer. The focus of our research is to understand normal cellular mechanisms that drive growth and differentiation of breast tissue, and those changes that lead to breast cancer. Nuclear regulatory proteins have been implicated in many different types of cancers and leukaemias. We aim to identify the key regulators in breast tissue, characterising both their structural properties and biological roles, with the ultimate view of understanding how they divert a normal cell to a cancerous cell.Read moreRead less
Progesterone Regulation Of Epithelial Expansion In The Normal Human Breast
Funder
National Health and Medical Research Council
Funding Amount
$556,393.00
Summary
The ovaries play a pivotal role in breast cancer. Progesterone increases breast cancer risk, and this is likely to be a subversion of its role in the normal breast, which is to participate in the normal expansion of the epithelial cells during the menstrual cycle, but how it does this is unknown. We will explore how progesterone influences cell types in the breast similar to those that become cancerous. This will uncover potential targets for prevention and treatment.
The Transcription Factor ZNF652: Deciphering Its Role In Breast Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$342,996.00
Summary
From our continuing research we have shown a protein called ZNF652 is involved in cancer. This proposal focuses on the role of this gene in the spread of cancer within the breast and to other organs. We will determine its role in a process where a cancer cell changes its characteristics to make it more likely to spread to other tissues. Our preliminary results suggest ZNF652 could be a marker that will predict poor prognosis. This proposal will further investigate this finding.
REVERSING EPITHELIAL TO MESENCHYMAL TRANSITION BY TARGETED EPIGENETIC EDITING IN BREAST CANCER
Funder
National Health and Medical Research Council
Funding Amount
$1,352,322.00
Summary
Cancer cell spread around the body involves changes in the cells which allow them to migrate into blood vessels, travel and then invade other organs, a process called epithelial mesenchymal transition (EMT). EMT also makes cells less sensitive to our best treatments. EMT involves switching on genes that activate these changes and switching off genes that silence them. We will develop therapy that will reverse this process, both reducing cancer spread and making cancer treatment more effective.
Transcriptional And Epigenetic Regulation Of Epithelial Mesenchymal Plasticity In Breast Cancer Dissemination
Funder
National Health and Medical Research Council
Funding Amount
$670,964.00
Summary
Fuelling the spread of breast cancer are small clusters or individual cancer cells that escape into the blood (CTC) and bone marrow (DTC). Comprehensive analysis of these is prohibited by difficulty in purifying them, and their small numbers. Using two novel, validated mouse models for these cells, we have devised an approach that will identify new diagnostic and therapeutic targets in these compartments. These will ultimately provide avenues to improve breast cancer survival.
A Novel Role For CBF? As A Regulator Of Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$682,415.00
Summary
Whole genome sequencing studies of human breast tumours identified a handful of common significantly mutated genes, all previously linked to breast cancer, except one, CBF?. Preliminary data from our lab now show that CBF? may be a new regulator of human breast cancer and metastasis. Using mice with altered CBF? levels, breast cancer models and human patient cohorts, this study aims to identify a novel role for CBF? as a new regulator of human breast cancer and potential therapeutic target.
Calcium Signaling And Epithelial-mesenchymal Transition: A New Approach To Identifying Pharmacological Targets For Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$561,645.00
Summary
The largest killer of women with breast cancer is disease that has spread e.g. to brain, bones, lungs. Once breast cancer has spread in this way to secondary sites, also known as metastatic disease, then there is limited treatment available and generally therapy is palliative only. Our work describes experiments that will help us understand the process of metastasis and provide new avenues for drug discovery in metastatic disease, thus helping women who have a poor prognosis.
Aberrant Mesenchymal-epithelial Transition: A Pathogenic Mechanism In Tissue Maintenance And Differentiation
Funder
National Health and Medical Research Council
Funding Amount
$522,299.00
Summary
The causative genetic factors associated with aberrant changes of cellular properties are identified by analysing the profile and the control mechanism of gene expression. Specifically,this project will reveal how the transition of different patterns of tissue organization may be manifested in birth defects and malignant diseases.